Discover why income-focused investors are eyeing HQH with its high dividend yield and discounted NAV, despite sector-specific ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Could you tell me about the firm? Mr. Kennedy: AllSource is a firm that focuses on high-net-worth and ultra-high-net-worth families, and we specialize in alternative investments. We like to say we ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.